Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organon & Co. filings document the regulatory record for a NYSE-listed global healthcare company with Women's Health and General Medicines portfolios, including biosimilars. Form 8-K reports cover operating and financial results, company presentations, clinical or regulatory disclosures, material agreements, and other material events tied to the healthcare portfolio.
Proxy and governance filings describe board composition, executive compensation, shareholder voting matters, equity-award disclosures, and common stock registered under the Exchange Act. The filing record also includes disclosures on board and committee changes, audit committee review matters, capital structure, and exhibits filed in Inline XBRL.
Organon & Co. insider filing (Form 4) reports that Juan Camilo Arjona Ferreira, Head of R&D & CMO and an officer of Organon (OGN), had 11,519 restricted stock units vest on August 11, 2025. Those vested units were recorded as acquisitions of common stock at $0 per share. The filing also shows a disposition of 4,122 shares sold at $9.22 per share on the same date.
The form reports beneficial ownership figures after the transactions: 28,899.355 shares reported after the RSU acquisition line and 24,777.355 shares reported after the sale line. The Form 4 was signed by an attorney-in-fact on August 12, 2025. The filing notes that each RSU equals one share and that a final vesting installment is scheduled for August 11, 2026.
Organon & Co. (OGN) Q2 2025 condensed summary: Revenues were $1.594 billion for the quarter and $3.107 billion for the six months, versus $1.607 billion and $3.229 billion in the prior-year periods. Net income fell to $145 million in Q2 2025 (Q2 2024: $195 million) and $232 million year-to-date (YTD 2025) versus $396 million YTD 2024. Diluted EPS was $0.56 for the quarter and $0.89 YTD versus $0.75 and $1.53 in the prior-year periods.
Key cash and balance sheet items: cash and equivalents declined to $599 million at June 30, 2025 from $675 million at Dec 31, 2024; total assets $13.5 billion; total long-term debt (net of current portion) $8.781 billion; weighted-average interest rate on borrowings 5.0% and average maturity ~5.1 years. Operating cash flow provided $295 million YTD; investing used $210 million, including Dermavant consideration.
Material corporate actions disclosed: Dermavant acquisition (aggregate consideration $581 million; contingent consideration fair value $383 million; $75 million regulatory milestone paid in Q1 2025); March 2025 U.S. rights for Tofidence from Biogen (intangible $51 million recognized; upfront paid in July 2025); July 2025 acquisition of Oss Biotech site (aggregate $25 million, $15 million paid). The Company repurchased $242 million of 5.125% 2031 notes in Q2, recording a $42 million pre-tax gain. The Company implemented restructuring reducing headcount ~6% and recorded $88 million of restructuring costs YTD. Effective tax rates increased (Q2 2025: 37.0% vs Q2 2024: 17.3%).